Your session is about to expire
← Back to Search
NMRA 335140 for Depression
Study Summary
This trial tests a drug (NMRA 335140) for symptoms of depression in people with Major Depressive Disorder. It has a screening period, a 6-week treatment period with either the drug or placebo, and an extension study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is it possible for people younger than 85 years old to participate in this scientific investigation?
"This research project requires that all participants are aged 18 to 65 years. For those younger and older than this limit, there are 219 clinical trials for patients under the age of 18 and 1024 for individuals over 65."
What is the highest number of participants that can take part in this research?
"Affirmative. Clinicaltrials.gov indicates that this medical research, which was first uploaded on September 20th 2023, is actively seeking participants. The trial requires 332 patients to be recruited from 3 distinct medical centres."
Has the FDA approved a dosage of 80 milligrams (mg) administered on a daily basis for NMRA-335140?
"Our team assigned a score of 3 to NMRA-335140 80 milligrams (mg) administered once daily (QD), as there is existing clinical data that confirms the medication's safety and efficacy."
Is the enrollment process for this experiment still open?
"Affirmative. According to clinicaltrials.gov, this medical trial which debuted on September 20th of 2023 is enrolling patients right now. 332 people are needed from 3 different healthcare centres."
Does my profile qualify me to join this research project?
"For admittance to this clinical trial, 332 depressed individuals aged 18-65 must meet a set of stringent criteria. These involve recording no more than 20% change in MADRS total score between Screening and Baseline; obtaining a primary DSM-5-TR diagnosis for MDD without psychotic features through SCID 5 CT at screening (which may be either their first or recurrent episode); confirming the major depressive episode independent assessment; having had symptoms for over 4 weeks but no longer than 12 months prior to the Screening Visit; and finally presenting with a minimum MADRS total score of 25 during both visits."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Segal Trials - Lauderhill, FL: < 24 hours
- Segal Trials - Miami Lakes, FL: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger